IDEAYA Biosciences to be Acquired for $1.1 Billion
Ticker: IDYA · Form: 8-K · Filed: Jul 9, 2024 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $952.7 million, $350.0 m, $40.40, $182.1 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, healthcare
TL;DR
IDEAYA is getting bought out for $1.1B cash, deal expected Q3 2024.
AI Summary
IDEAYA Biosciences, Inc. announced on July 9, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of HealthCare Royalty Partners IV, L.P. for $1.1 billion in cash. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition represents a significant financial event for IDEAYA Biosciences shareholders, providing them with a substantial cash payout and marking the end of its journey as an independent public company.
Risk Assessment
Risk Level: low — The filing is an announcement of a definitive agreement for acquisition, which is typically a straightforward event with defined terms.
Key Numbers
- $1.1 billion — Acquisition Price (Total cash consideration for IDEAYA Biosciences)
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Company being acquired
- HealthCare Royalty Partners IV, L.P. (company) — Acquiring entity
- $1.1 billion (dollar_amount) — Acquisition price
- July 9, 2024 (date) — Date of announcement and agreement
- third quarter of 2024 (date) — Expected closing period
FAQ
What is the total cash consideration for the acquisition of IDEAYA Biosciences?
The total cash consideration is $1.1 billion.
Who is acquiring IDEAYA Biosciences?
IDEAYA Biosciences is being acquired by a subsidiary of HealthCare Royalty Partners IV, L.P.
When was the definitive agreement for the acquisition announced?
The definitive agreement was announced on July 9, 2024.
When is the acquisition expected to close?
The transaction is expected to close in the third quarter of 2024.
What are the conditions for the closing of the acquisition?
The closing is subject to customary closing conditions.
Filing Stats: 761 words · 3 min read · ~3 pages · Grade level 13.4 · Accepted 2024-07-09 16:11:00
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
- $952.7 million — port that the Company had approximately $952.7 million in cash, cash equivalents and marketabl
- $350.0 m — ng an aggregate offering value of up to $350.0 million, referred to as its "at-the-marke
- $40.40 — ed average sales price of approximately $40.40 per share through its "at-the-market" o
- $182.1 million — 5, 2024, the Company had approximately $182.1 million of common stock remaining available for
Filing Documents
- d863971d8k.htm (8-K) — 24KB
- 0001193125-24-176736.txt ( ) — 143KB
- idya-20240709.xsd (EX-101.SCH) — 3KB
- idya-20240709_lab.xml (EX-101.LAB) — 18KB
- idya-20240709_pre.xml (EX-101.PRE) — 11KB
- d863971d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: July 9, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer